Our new study leverages deep learning-enabled analysis of the aggregation of multimodal clinical, biological, genomic, and radiomics data to identify and validate predictive signatures associated with response to immunotherapy and prognosis of patients with metastatic non-small cell lung cancer (NSCLC).
Hear from our CEO Jurgi Camblong as he recaps a major year for SOPHiA GENETICS. We're topping off a decade of Data Driven Medicine and looking toward the new year with determination.
SOPHiA GENETICS Hosts Symposium with GE Healthcare at RSNA 2021
We officially announced our collaboration with GE at RSNA where we co-hosted a comprehensive symposium about the role of the Radiologist and their use of emerging clinical technology as part of the healthcare revolution.
The information included in this document has been prepared for and is intended for viewing by a global audience. This document contains information about products and services which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indication for use. Please consult local sales representative.
Enter your email address to join our mailing list and receive the latest news and updates from SOPHiA GENETICS. You can unsubscribe by using the link integrated with the communication at any time. By clicking to “sign up”, you agree that SOPHiA GENETICS will process your data in accordance with its Privacy Policy
The advancement of genomic analysis technology revolutionizes breast cancer research, as it provides better breast tumor classifications, which then leads